CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer

Oncogene
Manuel IrimiaManel Esteller

Abstract

Imbalance of the Ras signaling pathway is a major hallmark of human cancer. In this context, activating point mutations of the K-ras oncogene are a common feature of many tumor types. The discovery of methylation-mediated silencing of the Ras-effector homologue RASSF1A has revealed another way by which this cellular pathway may be altered. Inactivation by hypermethylation of a RASSF1A homologue, NORE1A, has recently been observed in human cancers. If both K-ras and NORE1A act in the same pathway, simultaneous molecular lesions in the two genes in the same tumor should be a rare event. To test whether this inverse association exists, we have analysed the K-ras mutational status and NORE1A CpG island hypermethylation of 61 non-small-cell lung carcinomas and the methylation status of the two other Ras effectors, RASSF1A and HRASLS. No association was found between the methylation status of NORE1A, RASSF1A and HRASLS or the status of K-ras with respect to the latter two genes. However, our results demonstrate that the epigenetic alteration of NORE1A is confined to lung tumors with a wild-type K-ras: 88% (15 of 17) of the tumors with NORE1 hypermethylation did not harbor a K-ras mutation (P=0.008, Fisher's exact test). Thus, the mut...Continue Reading

References

Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Nov 1, 1996·Trends in Biochemical Sciences·C P Ponting, D R Benjamin
Jan 7, 1998·Experimental Cell Research·M Serrano
Apr 16, 1998·The Journal of Biological Chemistry·D VavvasX F Zhang
Sep 22, 2000·The Journal of Biological Chemistry·M D VosG J Clark
May 3, 2001·Journal of the National Cancer Institute·D G BurbeeJ D Minna
Jun 8, 2001·Proceedings of the National Academy of Sciences of the United States of America·K DreijerinkE R Zabarovsky
Feb 28, 2002·Current Biology : CB·Andrei KhokhlatchevJoseph Avruch
Apr 16, 2002·British Journal of Cancer·S TakahashiT Shirai
May 29, 2002·Oncogene·Manon van EngelandJames G Herman
Jun 18, 2002·Nature·Helen DaviesP Andrew Futreal
Jun 28, 2002·Cancer Cell·John D MinnaAdi F Gazdar
Aug 29, 2002·Nature·Harith RajagopalanVictor E Velculescu
Nov 26, 2002·The Journal of Biological Chemistry·Hong ChenJer-Tsong Hsieh
Apr 5, 2003·The Journal of Biological Chemistry·Michele D VosGeoffrey J Clark
Jun 5, 2003·Nature Reviews. Cancer·Marcos Malumbres, Mariano Barbacid

❮ Previous
Next ❯

Citations

Jan 12, 2005·The Journal of Pathology·Manel Esteller
Mar 16, 2006·Journal of the National Cancer Institute·Yasuhiro TadaChristoph Plass
Aug 25, 2007·The Journal of Clinical Investigation·Diego F CalvisiSnorri S Thorgeirsson
Feb 25, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Li-Li LiuChris Zhiyi Zhang
May 30, 2007·Oncogene·L B HessonF Latif
Aug 23, 2005·Expert Review of Anticancer Therapy·Edgardo S SantosRakesh Singal
Oct 30, 2010·Hormones and Behavior·Jennifer T WolstenholmeJessica J Connelly
May 4, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kazuya ShinmuraHaruhiko Sugimura
Feb 20, 2008·Experimental Cell Research·Samir Kumar Patra
Oct 9, 2007·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Annarita DestroMassimo Roncalli
May 3, 2008·International Journal of Cancer. Journal International Du Cancer·Janos GeliCatharina Larsson
Apr 19, 2006·International Journal of Cancer. Journal International Du Cancer·Sokbom KangSeung Myung Dong
Aug 19, 2007·Biochimica Et Biophysica Acta·Louise van der Weyden, David J Adams
Jun 12, 2016·Seminars in Cell & Developmental Biology·Howard DonningerGeoffrey J Clark
Apr 12, 2005·Annual Review of Pharmacology and Toxicology·Manel Esteller
Jun 28, 2005·Laboratory Investigation; a Journal of Technical Methods and Pathology·Nobuki NakamuraRicardo V Lloyd
Jan 20, 2006·The Journal of Biological Chemistry·Anna MoshnikovaAndrei V Khokhlatchev
May 4, 2005·Cancer Research·Angelo AgathanggelouFarida Latif
Dec 16, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J M A PijnenborgP G Groothuis
Sep 20, 2007·Journal of Cell Science·Howard DonningerGeoffrey J Clark
Oct 25, 2008·Molecular Cancer·Paul P AnglimIte A Laird-Offringa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.